WO2023217125A1 - 前列腺前体样细胞、细胞制剂及其制备方法和应用 - Google Patents

前列腺前体样细胞、细胞制剂及其制备方法和应用 Download PDF

Info

Publication number
WO2023217125A1
WO2023217125A1 PCT/CN2023/092958 CN2023092958W WO2023217125A1 WO 2023217125 A1 WO2023217125 A1 WO 2023217125A1 CN 2023092958 W CN2023092958 W CN 2023092958W WO 2023217125 A1 WO2023217125 A1 WO 2023217125A1
Authority
WO
WIPO (PCT)
Prior art keywords
prostate
precursor
cells
cell
content
Prior art date
Application number
PCT/CN2023/092958
Other languages
English (en)
French (fr)
Inventor
张琴
周伸奥
Original Assignee
上海赛立维生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海赛立维生物科技有限公司 filed Critical 上海赛立维生物科技有限公司
Publication of WO2023217125A1 publication Critical patent/WO2023217125A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)

Definitions

  • the present invention relates to the technical field of biotechnology, and in particular to a prostate precursor-like cell, a cell preparation and a preparation method and application thereof.
  • Chronic prostatitis/chronic pelvic pain syndrome CP/CPPS
  • benign prostatic hyperplasia BPH
  • the treatment of chronic prostatitis is mainly divided into drug treatment and non-drug treatment, which mainly include: 1. Antibiotics, which are the main clinical treatment for chronic prostatitis; 2. ⁇ -blockers, which eliminate the reflux of urine in the prostate during urination and reduce The incidence rate of chronic prostatitis; 3. High-frequency diathermy treatment.
  • the current first-line drugs for the treatment of prostatic hyperplasia are ⁇ -receptor blockers and 5 ⁇ -reductase inhibitors.
  • research on the mechanisms of disease and effective treatments has been progressing slowly.
  • One of the important reasons is that normal prostate cells cannot be cultured in vitro for a long time, which makes the research work unsustainable. Therefore, it is necessary to develop new prostate precursor-like cells and cell preparations to make prostate Continuous culture of somatic cells.
  • the object of the present invention is to provide a prostate precursor-like cell, a cell preparation and a preparation method and application thereof, which can enable the intrahepatic bile duct precursor-like cells to be continuously passaged, and at the same time, there is no need to take antibiotics after transplanting the prostate precursor-like cells. Detoxification can reduce harm to the human body.
  • the present invention provides a method for preparing prostate precursor-like cells, which includes the following steps:
  • S0 Provide prostate primary cells
  • the process of obtaining prostate primary cells is as follows:
  • the volume percentage of type I collagenase in sterile PBS buffer was 1%, and the volume percentage of neutral protease in sterile PBS buffer was 5%.
  • the centrifugation rate for each time was 1000g, and the centrifugation time was 3 minutes.
  • S1 The prostate primary cells in S0 are dedifferentiated and cultured using a reprogramming medium to obtain prostate precursor-like cells expressing at least one of the positive markers CD90, CD73, CD44 and SOX9, wherein the reprogramming medium Programming media includes basal media, inhibitors, and growth factors.
  • Optional also includes:
  • S2 Put the prostate primary cells into a reprogramming medium for dedifferentiation culture until the confluence of the prostate precursor-like cells is not less than 80%, and use trypsin digestion solution to perform dedifferentiation culture on the prostate precursor-like cells. The cells are digested to obtain prostate precursor-like cells.
  • the reprogramming medium also includes Wnt signaling pathway agonists, nutritional supplements and buffers.
  • the inhibitors include ROCK kinase inhibitors and A83-01 inhibitors that inhibit the TGF- ⁇ signaling pathway.
  • the content of the ROCK kinase inhibitor is 5-20 ⁇ M, and the content of the A83-01 inhibitor is 1-5 ⁇ M based on the content of the basal culture medium.
  • the growth factors include EGF, bFGF, Noggin and R-spondin1.
  • the content of EGF is 10-50ng/mL
  • the content of bFGF is 10-50ng/m
  • the content of Noggin is 1-10ng/mL
  • the content of R-spondin1 is 10-30ng/mL.
  • the prostate precursor-like cells do not express CD34, CD45, HLA-DR, HLA-DP and HLA-DQ.
  • the present invention also provides an application of the prostate precursor-like cells.
  • the prostate precursor-like cells are used to prepare a prostate precursor-like cell preparation for treating prostatitis or prostatic hyperplasia. Using the prostate precursor-like cells The effect on prostatitis was examined after the preparation intervened in the in vivo animal model.
  • the animal model includes a drug-induced prostatitis or prostatic hyperplasia model.
  • the present invention also provides a prostate precursor-like cell preparation, including the prostate precursor-like cells expressing at least one of the positive markers CD90, CD73, CD44 and SOX9, and a pharmaceutically acceptable carrier.
  • the present invention also provides an application of a prostate precursor-like cell preparation, using the prostate precursor-like cell preparation to intervene in an in vivo animal model.
  • the present invention obtains prostate precursor-like cells that express at least one of the positive markers CD90, CD73, CD44 and SOX9 through reprogramming culture medium and do not express MHC class II molecules. Therefore, there is no need to take anti-extrusion drugs after transplanting prostate precursor-like cells, which can reduce harm to the human body.
  • the prostate precursor-like cells can be continuously cultured in vitro.
  • Figure 1 is a schematic diagram of the morphology of prostate precursor-like cells provided by the present invention under an optical microscope
  • Figure 2 is a comparison chart of the basal cell marker content of prostate precursor-like cells in the present invention after expansion and culture in reprogramming medium and basal medium respectively;
  • Figure 3 is a comparison chart of the luminal cell marker content of prostate precursor-like cells in the present invention after expansion and culture in reprogramming medium and basal medium respectively;
  • Figure 4 is a comparison chart of stem cell marker content in prostate precursor-like cells of the present invention after expansion and culture in reprogramming medium and basal medium respectively;
  • Figure 5 is a comparison chart of prostate-specific marker content in prostate precursor-like cells of the present invention after amplification and culture in reprogramming medium and basal medium respectively;
  • Figure 6 is a schematic diagram of the gene expression marker CD44 of prostate precursor-like cells according to an embodiment of the present invention.
  • Figure 7 is a schematic diagram of the gene expression marker CD73 of prostate precursor-like cells according to an embodiment of the present invention.
  • Figure 8 is a schematic diagram of the gene expression marker HLA-DRPQ of prostate precursor-like cells according to an embodiment of the present invention.
  • Figure 9 is a schematic diagram of the gene expression marker SOX9 of prostate precursor-like cells according to an embodiment of the present invention.
  • Figure 10 is a schematic diagram of the gene expression marker CD90 of prostate precursor-like cells according to an embodiment of the present invention.
  • Figure 11 is a schematic diagram of the gene expression marker CD34 of prostate precursor-like cells according to an embodiment of the present invention.
  • Figure 12 is a schematic diagram of the gene expression marker CD45 of prostate precursor-like cells according to an embodiment of the present invention.
  • Figure 13 is a schematic diagram of the establishment process of the rat prostatitis model in the present invention.
  • Figure 14 is a schematic diagram of the detection of IL-6 expression levels using Elisa detection in the sham operation group, blank control group and prostate precursor-like cell treatment group;
  • Figure 15 is a schematic diagram of the Elisa detection method for detecting IL-1a expression levels in the sham operation group, blank control group and prostate precursor-like cell treatment group;
  • Figure 16 is a fluorescence photo of HE staining of prostate case sections in the sham operation group, blank control group and prostate precursor-like cell treatment group respectively in the present invention
  • Figure 17 shows the pathological results of the prostatic hyperplasia model in the present invention.
  • Chronic prostatitis also known as chronic pelvic pain syndrome (CP/CPPS)
  • CP/CPPS chronic pelvic pain syndrome
  • Drug therapy mainly includes: 1. Antibiotics.
  • Antibiotic drugs have the characteristics of high fat solubility, low protein binding rate, small molecular weight and high degree of dissociation.
  • Antibiotic drugs such as azithromycin have high levels of tissue penetration and are effective against bacteria and mycoplasma.
  • Non-drug treatments include pelvic floor physical therapy, myofascial trigger point release, acupuncture, psychological support, electrical body shock wave therapy, localized heat therapy, and more.
  • Benign Prostate Hyperplasia is a common disease in elderly men. It is mainly characterized by frequent urination, urgency, progressive worsening of urination difficulty, weak urination, shortened urinary course, incomplete urination or dripping. With the aging of my country's population, its incidence has been on the rise in recent years. Prostatic hyperplasia is currently divided into histological prostatic hyperplasia and clinical prostatic hyperplasia. Histological prostatic hyperplasia is a physiological aging process. Clinical prostatic hyperplasia is a pathological type, characterized by enlargement of the prostate and bladder outlet obstruction. Two important factors for the occurrence of prostatic hyperplasia are: advanced age and functional testicles.
  • the androgen secreted by the testicles is converted into dihydrotestosterone to play a role. It is required for the development of male external genitalia, the growth of the prostate in adolescence, and prostatic hyperplasia in the elderly. Presence of dihydrotestosterone. Androgens can also stimulate the production of growth factors.
  • the prostate can produce a variety of growth factors, including epidermal growth factor (EGF), fibroblast growth factor (FGF), ⁇ -converting growth factor (TGF- ⁇ ), etc. Growth factors and growth Only with a relative balance of inhibitory factors can the prostate develop and grow normally. There are three main ways to treat BPH: 1.
  • Drug treatment can inhibit the production of dihydrotestosterone and can inhibit the continued proliferation of prostate tissue; prostate receptor ⁇ 1 antagonists ( ⁇ -blockers), It can relieve the symptoms of dysuria, but drug treatment only has a certain effect on patients with mild prostatic hyperplasia, and the effect of drug treatment on moderate to severe patients is significantly reduced. Patients with moderate and severe prostatic hyperplasia require surgical treatment to relieve the obstruction; 2. Open surgery includes: suprapubic transvesical prostatectomy, retropubic prostatectomy, and retropubic urethra-preserving prostatectomy. Open surgery involves large trauma and many complications.
  • minimally invasive surgeries include: transurethral resection of the prostate, laser treatment, minimally invasive surgery Wave treatment, etc., has less trauma and faster recovery, but the condition may recur.
  • Elderly patients with prostatic hyperplasia generally suffer from multiple diseases at the same time due to their age and may not be eligible for surgery.
  • the prostate is the male sexual organ. It secretes prostatic fluid accounting for 30% of semen.
  • the prostate duct is arranged by pseudostratified epithelial cells. There are three main cell types: 1) Secreting luminal cells, which contain cytokeratin CK8/CK18 and androgen receptors. (AR) and prostate-specific antigen (PSA) as markers; 2) basal cells, marked by CK5/CK14/p63; 3) rare neuroendocrine cells.
  • A prostate-specific antigen
  • Basal cells show duality, that is, they can produce both luminal and basal cell lines, indicating that basal cells have potential. Studies have also shown that in human mature prostate, both basal cells and luminal cells contain stem cell activity. Multipotent basal stem cells can promote the differentiation of prostate basal, luminal, and neuroendocrine cell lineages.
  • the prostate epithelium is composed of basal cells, secretory luminal cells and rare neuroendocrine cells. Because the prostate epithelium undergoes repeated androgen deprivation and recovery in mice and rats, It has the ability to degenerate and regenerate after recovery and can be used as a cell source for studying prostate stem cell biology. The researchers demonstrated the presence of prostate stem-like cells in both the basal and luminal epithelium of the prostate through in vivo renal subcapsular tissue regeneration, cell division models, and in vitro organoid formation.
  • Multipotent basal stem cells can promote differentiation of prostate basal, luminal, and neuroendocrine cell lineages, particularly during early postnatal development.
  • Multipotent basal stem cells are located exclusively in the paraurethral niche and generate epithelial progenitor cells in a directed migration manner.
  • basal and luminal cell lineages are maintained independently.
  • Stem cell-related markers CD117, CD133, CD44, Trop2, CD49f, Sca1, etc. are present in basal cells and luminal cells.
  • ⁇ -receptor inhibitors have a quick onset of action and are effective for different degrees of prostatic hyperplasia in different locations. However, they are only effective for patients with mild symptoms and small prostate volume, and may cause postural instability. Sexual hypotension, 5a reductase inhibitors can reduce the size of the prostate, reverse the progression of the disease, and improve symptoms, but the onset of effect is relatively slow. It generally requires continuous medication for more than 2-3 months to take effect. In addition, erectile dysfunction may occur. Disorders, low libido and other diseases, plant medicine treats prostate
  • hyperplasia The mechanism of hyperplasia is currently unclear, and there is still a lack of high-quality, large-scale, placebo-controlled, long-term clinical trials to further test the effectiveness and safety of botanical therapies.
  • embodiments of the present invention provide a method for preparing prostate precursor-like cells, which includes the following steps:
  • the preparation process of prostate primary cells is as follows:
  • type I collagenase accounts for 1% of the volume of sterile PBS buffer
  • neutral protease accounts for 1% of the volume of sterile PBS buffer. The percentage is 5%.
  • the centrifugation rate for each time was 1000g and the centrifugation time was 3 minutes.
  • type I collagenase comes from Merck.
  • Neutral proteases are derived from source leaf organisms.
  • S1 The prostate primary cells in S0 are dedifferentiated and cultured using a reprogramming medium to obtain prostate precursor-like cells expressing at least one of the positive markers CD90, CD73, CD44 and SOX9, wherein the reprogramming medium Programming media includes basal media, inhibitors, and growth factors.
  • the basal culture medium is DMEM/F12 culture medium.
  • the method for preparing prostate precursor-like cells further includes: S2: placing the prostate primary cells in a reprogramming medium for dedifferentiation and culturing until the prostate precursor-like cells The degree of fusion is not less than 80%, and the prostate precursor-like cells are digested using trypsin digestion solution to obtain prostate precursor-like cells.
  • S2 placing the prostate primary cells in a reprogramming medium for dedifferentiation and culturing until the prostate precursor-like cells The degree of fusion is not less than 80%, and the prostate precursor-like cells are digested using trypsin digestion solution to obtain prostate precursor-like cells.
  • the reprogramming culture medium further includes a Wnt signaling pathway agonist, nutritional supplements and buffer.
  • the Wnt signaling pathway agonist is CHIR99021, and the content of the Wnt signaling pathway agonist is 3 ⁇ M based on the content of the basal culture medium.
  • the nutritional supplement includes N2 (1X) and B27 (1X).
  • the content of N2 (1X) is 0.5% of the final volume of the culture medium.
  • the content of B27 (1X) is the final volume of the medium 1%.
  • the inhibitor includes a ROCK kinase inhibitor and an A83-01 inhibitor that inhibits the TGF- ⁇ signaling pathway.
  • the ROCK kinase inhibitor is Y-27632. Based on the content of the basal culture medium, the content of the ROCK kinase inhibitor is 5-20 ⁇ M, and the content of the A83-01 inhibitor is 1-5 ⁇ M. Among them, the A83-01 acts as an inhibitor of Alk3/4/5 to inhibit the TGF- ⁇ signaling pathway and prevent the proliferation of prostate precursor-like cells from being blocked.
  • the growth factors include EGF, bFGF, Noggin and R-spondin1.
  • EGF EGF
  • bFGF EGF
  • Noggin EGF
  • R-spondin1 EGF
  • the content of the basal culture medium the content of the basal culture medium is 10-50ng/mL
  • the content of the bFGF is 10-50ng/mL
  • the content of Noggin is 1-10ng/mL
  • the R -The content of spondin1 is 10-30ng/mL.
  • the growth factor Noggin is a BMP-4 antagonist. Antagonizing BMP activity can cause stem cells to proliferate while maintaining their undifferentiated state.
  • the growth factor R-spondin1 can regulate the Wnt/ ⁇ -catenin signaling pathway and can be used to maintain prostate precursor-like cell proliferation.
  • the prostate precursor-like cells do not express CD34, CD45, HLA-DR, HLA-DP and HLA-DQ.
  • the CD34, CD45, HLA-DR, HLA-DP and HLA-DQ belong to MHC class II molecules.
  • the prostate precursor-like cells obtained in the present invention do not express MHC class II molecules. Therefore, the prostate precursor-like cells cannot be transplanted after transplantation. It is necessary to take anti-excretion drugs, which can reduce harm to the human body.
  • the prostate precursor-like cells of the present invention are safer in treating prostatitis, have a wider range of applications, and are more acceptable to patients.
  • the present invention also provides a prostate precursor-like cell, which is prepared by the preparation method of prostate precursor-like cells and can specifically express at least one of the positive markers CD90, CD73, CD44 and SOX9.
  • the present invention also provides an application of the prostate precursor-like cells.
  • the prostate precursor-like cells are used to prepare a prostate precursor-like cell preparation for treating prostatitis or prostatic hyperplasia. Using the prostate precursor-like cells The effect on prostatitis was examined after the preparation intervened in the in vivo animal model.
  • the animal model includes a drug-induced prostatitis or prostatic hyperplasia model.
  • the present invention also provides a prostate precursor-like cell preparation, including the prostate precursor-like cells expressing at least one of the positive markers CD90, CD73, CD44 and SOX9, and a pharmaceutically acceptable carrier.
  • the present invention also provides an application of a prostate precursor-like cell preparation, using the prostate precursor-like cell preparation to intervene in an in vivo animal model.
  • pathological examination showed that the prostate tissue was normal prostate tissue.
  • the tissue removed after clinical benign prostatic hyperplasia surgery or the normal prostate tissue donated by a donor are surgical samples from patients who are no more than 70 years old.
  • the patient has no infectious virus infection after medical examination, and the patient has no infectious virus infection before surgery. No steroids have been used within 6 months.
  • the patient was fully informed about the purpose of obtaining surgical samples before surgery and signed an informed consent form.
  • the prostate primary cells include basal cells, luminal cells and stem cells.
  • the volume percentage of type I collagenase in sterile PBS buffer was 1%, and the volume percentage of neutral protease in sterile PBS buffer was 5%.
  • the centrifugation rate for each time was 1000g and the centrifugation time was 3 minutes.
  • the components of the reprogramming medium include: based on the volume of the reprogramming medium, the basal medium DMEM/F12 (from Wuhan Prosai Life Technology Co., Ltd.), the epithelial cell growth factor EGF with a content of 20ng/mL, the content Basic fibroblast growth factor bFGF at 50ng/mL in 0.5% nutritional supplement N2 (1X) of the final volume of medium and 1% B27 nutritional supplement (1X) in the final volume of medium.
  • ROCK kinase inhibitor Y-27632 at 5-20 ⁇ M
  • Wnt signaling pathway agonist CHIR99021 at 3 ⁇ M
  • TGF- ⁇ signaling inhibitor A8301 at 1-5 ⁇ M
  • bile duct precursor-like promoter at 1-10ng/mL
  • Cell proliferation was stimulated by Noggin and R-spondin1 at a content of 10-30ng/mL.
  • the expansion culture can also be called subculture, and the prostate precursor-like cells can be Continuous generation.
  • the present invention also provides a schematic diagram of the morphology of prostate precursor-like cells under an optical microscope.
  • Figure 1 is a schematic diagram of the morphology of prostate precursor-like cells provided by the present invention under an optical microscope; from As can be seen in Figure 1, the prostate precursor-like The cells were polygonal and grew in aggregate. It can be seen that prostate precursor-like cells can be expanded in vitro through the reprogramming medium in this example.
  • Prostate precursor-like cells were cultured in reprogramming medium and basal medium respectively, and the marker results were analyzed.
  • Reprogramming medium and basal medium were used to culture prostate precursor-like cells in vitro.
  • Basic medium culture group Place prostate precursor-like cells in a 6-well plate at an inoculation area of 10,000 cells/cm2, add 2 ml of basic medium to each well for dedifferentiation culture, and use trypsin digestion solution to digest the prostate precursors. After digesting the sample cells for 1-5 minutes, continue to use basal medium for expansion culture.
  • Figure 2 is a comparison chart of the basal cell marker content of prostate precursor-like cells in the present invention after amplification and culture in reprogramming medium and basal medium respectively;
  • Figure 3 is a comparison diagram of prostate precursor-like cells in the present invention after being reprogrammed. Comparison of the luminal cell marker content between the culture medium and the basic culture medium after expansion and culture;
  • Figure 4 is a prostate precursor sample in the present invention A comparison chart of stem cell marker content after the cells have been expanded and cultured in reprogramming medium and basal medium respectively;
  • Figure 5 shows the content of stem cell markers in the prostate precursor-like cells of the present invention after they have been expanded and cultured in reprogramming medium and basal medium. Prostate-specific marker content comparison chart.
  • each marker in Figures 2, 3, 4 and 5 corresponds to two rectangular columns.
  • the rectangular columns represent the relative content of the marker, and the rectangular column on the left corresponds to the amplified culture in the basal medium.
  • the results on the right correspond to the results of expansion culture in reprogramming medium.
  • the basal cell markers in Figure 2 include CK14, CK5 and P63. As can be seen from Figure 2, the results of the above markers expanded and cultured in the reprogramming medium are higher than those in the basal medium. It can be seen that , prostate precursor-like cells can expand and culture more basal cells in reprogramming medium than in basal medium.
  • the luminal cell markers in Figure 3 include CK18, CK8 and AR. As can be seen from Figure 3, the results of the expansion and culture of the above markers in reprogramming medium are higher than the results of expansion and culture in basal medium. It can be seen that , prostate precursor-like cells can expand and culture more basal cells in reprogramming medium than in basal medium.
  • the stem cell markers in Figure 4 include CD44, CD49b, CD133, CD117, Trop2, CD491, Sca-1 and p63.
  • the results of expansion culture in reprogramming medium are higher than the results of expansion culture in basal medium. It can be seen that, Prostate precursor-like cells can expand and culture more cells with stemness characteristics in reprogramming medium than in basal medium.
  • the prostate-specific markers in Figure 5 include PBSN and MLX3-1. As can be seen from Figure 5, the results of the above markers in the reprogramming medium amplification culture are lower than those in the basic culture medium. The results of medium expansion culture showed that the reprogramming medium can maintain the dedifferentiated state of prostate precursor cells and do not express mature prostate tissue cell markers.
  • Figure 6 is a schematic diagram of the gene expression marker CD44 of prostate precursor-like cells in an embodiment of the present invention
  • Figure 7 is a schematic diagram of the gene expression marker CD73 of prostate precursor-like cells in an embodiment of the present invention
  • Figure 8 is a schematic diagram of the present invention
  • Figure 9 is a schematic diagram of the gene expression marker SOX9 of prostate precursor-like cells according to an embodiment of the present invention
  • Figure 10 is a schematic diagram of the implementation of the present invention Schematic diagram of the gene expression marker CD90 in prostate precursor-like cells in an example.
  • the positive rate of the negative peak of the marker HLA-DRPQ is %.
  • the negative rate of the negative peak is greater than 98%, indicating that the prostate precursor-like cells negatively express the marker. Therefore, the gastric mucosal epithelial precursor-like cells of the present invention Negative expression of HLA-DR, HLA-DP and HLA-DQ.
  • the positive rate of the positive peak of the marker CD44 is 99.7%
  • the positive rate of the positive peak of the marker CD73 is 99.8%
  • the positive rate of the positive peak of the marker SOX9 is 87.9%.
  • the positive rate of the positive peak of marker CD90 is 74.6%.
  • the positive rate of the positive peak is between 70-99%, indicating that prostate precursor-like cells positively express the marker. Therefore, the prostate precursor-like cells of the present invention positively express CD44, CD73, SOX9 and CD90.
  • This example provides a modeling method for a rat acute prostatitis model, and uses prostate precursor-like cells to intervene in the rat prostatitis model, and examines the effect of prostate precursor-like cells on prostatitis.
  • male sexually mature 10-12 week old wild-type SD rats purchased from Beijing Vitong Lever were used for modeling.
  • the average weight of rats reaches 300g.
  • rats were intraperitoneally injected with 10% chloral hydrate, one to two After a few minutes, lay the patient down on a clean table, inject 0.1 ml of lidocaine hydrochloride subcutaneously on both sides of the midline 2 to 3 cm above the base of the penis, make a 1 to 2 cm longitudinal incision, and incise the skin and fascia layer by layer.
  • To reach the muscle tissue make a small incision downward from the epithelial muscle. After the feeling of stepping on the air appears, use a hemostatic forceps to enter the abdominal cavity and bluntly separate the tissue. Lift the bladder and find the darker lobes on both sides of the prostate behind it. Inject 3% carrageenan on both sides.
  • FIG. 13 shows the rat prostate in the present invention. Schematic diagram of the inflammation model establishment process.
  • the rat prostatitis model was randomly divided into a sham operation group (3 rats), a blank control group (3 rats), and a cell treatment group (3 rats).
  • the rats were intraperitoneally injected with 10% chloral hydrate. After one to two minutes, they were placed supine on a clean table, and 0.1 ml lidocaine hydrochloride was injected subcutaneously on both sides of the midline 2 to 3 cm above the base of the penis.
  • a hemostatic forceps to enter the abdominal cavity and bluntly dissect the tissue to lift the bladder and find the color behind it.
  • Prostate precursor-like cell treatment group During modeling, 50ul of prostate precursor-like cells were injected into both lobes of the rats in the cell treatment group at the same time as 1E+06 50ul+50ul matrigel. Matrigel; one week after modeling, 50ul of prostate precursor-like cells were injected into both lobes of the rats in the cell therapy group again and 1E+06 50ul+50ul matrigel was injected.
  • IL-1a and IL-6 are inflammatory molecules.
  • Figure 14 is a schematic diagram of the sham operation group, blank control group and prostate precursor-like cell treatment group using Elisa detection method to detect IL-6 expression levels
  • Figure 15 is a sham operation group, blank control group and prostate precursor-like cell treatment group using Elisa Schematic diagram of detection method to detect IL-1a expression level.
  • Figure 16 is a fluorescence photo of HE staining of prostate case sections in the sham operation group, blank control group and prostate precursor-like cell treatment group respectively in the present invention.
  • the prostate tissue glands in the sham operation group were intact and there was no infiltration of inflammatory cells.
  • the blank control group varying amounts of tissue degeneration, edema or hyperplasia of the prostate gland, and a large amount of inflammatory cell infiltration in the interstitium were seen.
  • the prostate tissue glands in the sham operation group were intact and there was no infiltration of inflammatory cells.
  • the blank control group varying amounts of tissue degeneration, prostate gland edema or hyperplasia, and a large amount of inflammatory cells infiltration in the interstitium were seen in the precursor-like cell treatment group.
  • the relative inflammatory cell infiltration was significantly decreased compared with the blank control group.
  • Modeling process Testosterone propionate, 50 mg per kilogram, subcutaneously injected every other day for 3 weeks.
  • Sham operation group In this example, male 10-12 week old wild-type SD rats purchased from Beijing Vitong Lever were used for modeling. The average weight of the rats reached 300g. There were 3 rats in each group. Testosterone propionate was injected subcutaneously at a dose of 50mg per kilogram, a total of 2 times, with an interval of 1 day. No cell administration treatment was performed.
  • Blank control group No operation is performed.
  • the animals in the experimental group and sham operation group are enrolled at the same time and kept continuously.
  • Prostate precursor-like cell treatment group Rats were injected intraperitoneally with 10% chloral hydrate. After one to two minutes, they were placed supine on a clean table, and 0.1 ml hydrochloric acid was injected subcutaneously on both sides of the midline 2 to 3 cm above the base of the penis. With lidocaine, make a 1 to 2cm longitudinal incision, cut through the skin and fascia layer by layer, and make a small incision downward to reach the muscle tissue and the epithelial muscle. When a feeling of stepping on the air appears, use a hemostatic forceps to enter the abdominal cavity and bluntly dissect the tissue to lift the bladder. Find the darker lobes on both sides of the prostate at the back. After mixing 1E+06/50ul of prostate precursor-like cells with 50ul of matrigel, inject it into both lobes of the prostate; and subcutaneously inject testosterone propionate at a dose of 50 mg per kilogram.
  • testosterone propionate was injected subcutaneously again at a dose of 50 mg per kilogram.
  • Figure 17 shows the pathological results of the prostatic hyperplasia model of the present invention.
  • the prosthetic hand In the surgical group, the prostate tissue glands were intact without inflammatory cell infiltration.
  • tissue degeneration and prostate gland hyperplasia were seen.
  • tissue degeneration and gland hyperplasia were significantly reduced compared with the blank control group.
  • prostate precursor-like cell markers were cells that positively expressed CD90, CD73, CD44 and SOX9, and showed a typical prostatic appearance when cultured in vitro. Somatic cell characteristics. It can be used for subsequent research on the mechanisms of prostate inflammation and hyperplasia, and can conduct various experiments at the cellular level in vitro.
  • the cultured prostate precursor-like cells can significantly reduce the levels of blood inflammatory factors IL-6 and IL-2a and the degree of prostate tissue inflammation in prostatitis models after cell reinfusion treatment. Moreover, in the benign prostatic hyperplasia model, prostatic hyperplasia can be improved after cell infusion.
  • prostate precursor-like cells because the proteins CD34, CD45, HLA-DR, HLA-DP and HLA-DQ related to immune rejection are not expressed on the surface of prostate precursor-like cells, allogeneic reinfusion of prostate precursor-like cells can be achieved to achieve clinical benign results.
  • the tissue removed after benign prostatic hyperplasia surgery or the normal prostate tissue donated by the donor is used as the source.
  • the primary prostate cells obtained after digestion of the prostate tissue are used as seed cells. They are cultured in vitro using reprogramming medium to obtain positive expression of CD90, CD73, and CD44. and SOX9 prostate precursor-like cells, and In vitro amplification to establish a cell seed bank.
  • prostate precursor-like cells can be directly injected in situ.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

本发明提供了一种前列腺前体样细胞、细胞制剂及其制备方法和应用，包括以下步骤：S0：提供前列腺原代细胞；S1：对所述S0中的前列腺原代细胞使用重编程培养基进行退分化培养以获得表达阳性标志物CD90、CD73、CD44和SOX9中至少一种的前列腺前体样细胞，其中，所述重编程培养基包括基础培养基、抑制剂和生长因子；本发明前列腺前体样细胞能够在体外实现持续培养，可以减少对人身体的伤害。

Description

前列腺前体样细胞、细胞制剂及其制备方法和应用
本申请要求2022年05月10日提交的申请号为2022105036786，发明名称为“生物制剂、细胞衍生物及制备方法和应用”的中国专利申请的优先权。上述申请的内容以引用方式被包含于此。
技术领域
本发明涉及生物技术技术领域，尤其涉及一种前列腺前体样细胞、细胞制剂及其制备方法和应用。
背景技术
慢性前列腺炎症/慢性盆腔疼痛综合征(Chronic prostatitis/Chronic pelvic pain syndrome，CP/CPPS)和前列腺增生(Benign prostatic hyperplasia，BPH)属于男科疾病，对患者生活质量造成的影响巨大。慢性前列腺炎症治疗主要分药品治疗和非药物治疗，主要包括：1，抗生素，是临床上治疗慢性前列腺炎主要方式；2，α受体阻滞剂，消除排尿时前列腺内尿液返流，减少慢性前列腺炎的发生几率；3，高频透热治疗。目前治疗前列腺增生的一线药物是α受体阻剂和5α还原酶抑制剂。但是疾病产生的机制以及有效的治疗方式，相关研究一直进展缓慢，其中很重要的一个原因是前列腺正常细胞无法在体外长期培养，造成研究工作无法持续开展。因此，有必要开发新型的前列腺前体样细胞及细胞制剂以使前列腺前 体样细胞的持续培养。
发明内容
本发明的目的在于提供一种前列腺前体样细胞、细胞制剂及其制备方法和应用，能够使得肝内胆管前体样细胞能够连续传代，同时，在移植前列腺前体样细胞后不需要服用抗排药，可以减少对人身体的伤害。
为实现上述目的，本发明提供了一种前列腺前体样细胞的制备方法，包括以下步骤：
S0：提供前列腺原代细胞；
前列腺原代细胞获得过程如下：
提供成熟的前列腺组织；使用无菌PBS缓冲液对成熟的前列腺组织进行清洗和灭菌处理后，使用由Ⅰ型胶原酶、无菌PBS缓冲液和中性蛋白酶消化液组成的3毫升细胞消化液在37摄氏度下对组织消化90分钟，从而获取原代细胞悬液。接着，使用70微米的无菌筛网对所述原代细胞悬液在无菌PBS缓冲液的辅助下进行筛网分选，收集滤液并去除粘液和未消化的组织，以完成筛网分选。然后，将得到的滤液离心并去除上清后，向得到的沉淀物内加入红细胞溶解平衡液进行重悬后再次离心并重复上述过程直至再次离心后在细胞沉淀中观察不到红细胞为止，以完成红细胞裂解去除，从而得到前列腺原代细胞。
值得注意的是，在前列腺原代细胞制备过程，Ⅰ型胶原酶占无菌PBS缓冲液的体积百分比为1％，中性蛋白酶占无菌PBS缓冲液的体积百分比为5％。每次离心的速率均为1000g，离心时间均为3分钟。
S1：对所述S0中的前列腺原代细胞使用重编程培养基进行退分化培养以获得表达阳性标志物CD90、CD73、CD44和SOX9中至少一种的前列腺前体样细胞，其中，所述重编程培养基包括基础培养基、抑制剂和生长因子。
可选的，还包括：
S2：将所述前列腺原代细胞放入重编程培养基中进行退分化培养，直至所述前列腺前体样细胞的融合度不低于80％，使用胰酶消化液对所述前列腺前体样细胞进行消化处理，以得到前列腺前体样细胞。
可选的，所述重编程培养基还包括Wnt信号通路激动剂、营养补充剂和缓冲液。
可选的，所述抑制剂包括抑制TGF-β信号通路的ROCK激酶抑制剂和A83-01抑制剂。
可选的，以占所述基础培养基的含量计，所述ROCK激酶抑制剂的含量为5-20μM，所述A83-01抑制剂的含量为1-5μM。
可选的，所述生长因子包括EGF、bFGF、Noggin和R-spondin1。
可选的，以占所述基础培养基的含量计，EGF的含量为10-50ng/mL，所述bFGF的含量为10-50ng/m，所述Noggin的含量为1-10ng/mL，所述R-spondin1的含量为10-30ng/mL。
可选的，所述前列腺前体样细胞不表达CD34、CD45、HLA-DR、HLA-DP和HLA-DQ。
本发明还提供了一种所述的前列腺前体样细胞的应用，所述前列腺前体样细胞用于制备治疗前列腺炎或前列腺增生的前列腺前体样细胞制剂，使用所述前列腺前体样细胞制剂干预体内动物模型后考察对前列腺炎的影响。
可选的，所述动物模型包括药物诱导的前列腺炎或前列腺增生模型。
本发明还提供了一种前列腺前体样细胞制剂，包括所述的表达阳性标志物CD90、CD73、CD44和SOX9中至少一种的前列腺前体样细胞，以及药学上可接受的载体。
本发明还提供了一种前列腺前体样细胞制剂的应用，使用所述的前列腺前体样细胞制剂干预体内动物模型。
本发明的有益效果在于：
本发明通过重编程培养基培养得到表达阳性标志物CD90、CD73、CD44和SOX9中至少一种的前列腺前体样细胞，不表达MHC二类分子， 因此在移植前列腺前体样细胞后不需要服用抗排药，可以减少对人身体的伤害，该前列腺前体样细胞能够在体外实现持续培养。
附图说明
图1为本发明提供的前列腺前体样细胞的光学显微下的形态示意图；
图2为本发明中前列腺前体样细胞分别经过重编程培养基和基础培养基扩增培养后其中的基底细胞标志物含量对照图；
图3为本发明中前列腺前体样细胞分别经过重编程培养基和基础培养基扩增培养后其中的腔细胞标志物含量对照图；
图4为本发明中前列腺前体样细胞分别经过重编程培养基和基础培养基扩增培养后其中的干细胞标志物含量对照图；
图5为本发明中前列腺前体样细胞分别经过重编程培养基和基础培养基扩增培养后其中的前列腺特异性标志物含量对照图；
图6为本发明实施例的前列腺前体样细胞的基因表达标志物CD44的情况示意图；
图7为本发明实施例的前列腺前体样细胞的基因表达标志物CD73的情况示意图；
图8为本发明实施例的前列腺前体样细胞的基因表达标志物HLA-DRPQ的情况示意图；
图9为本发明实施例的前列腺前体样细胞的基因表达标志物SOX9的情况示意图；
图10为本发明实施例的前列腺前体样细胞的基因表达标志物CD90的情况示意图；
图11为本发明实施例的前列腺前体样细胞的基因表达标志物CD34的情况示意图；
图12为本发明实施例的前列腺前体样细胞的基因表达标志物CD45的情况示意图；
图13为本发明中大鼠前列腺炎模型建立过程示意图；
图14为假手术组、空白对照组和前列腺前体样细胞治疗组采用Elisa检测法检测IL-6表达水平示意图；
图15为假手术组、空白对照组和前列腺前体样细胞治疗组采用Elisa检测法检测IL-1a表达水平示意图；
图16为本发明中假手术组、空白对照组和前列腺前体样细胞治疗组中分别对前列腺病例切片HE染色的荧光照片；
图17为本发明中前列腺增生模型病理结果。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚，下面将结合本发明的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例是本发明的一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。除非另外定义，此处使用的技术术语或者科学术语应当为本发明所属领域内具有一般技能的人士所理解的通常意义。本文中使用的“包括”等类似的词语意指出现该词前面的元件或者物件涵盖出现在该词后面列举的元件或者物件及其等同，而不排除其他元件或者物件。
慢性前列腺炎，又叫慢性盆腔疼痛综合征(Chronic prostatitis/Chronic pelvic pain syndrome，CP/CPPS)是泌尿外科、男科常见疾病之一，以尿路症状和慢性疼痛障碍为主要征象，占前列腺炎的90～95％。CP/CPPS涉及复杂的病理生理机制，包括隐性感染、免疫、炎症、神经、内分泌、前列腺内尿反流、氧化应激和心理因素等，且不同因素之间经常交叉影响。药物疗法主要包括：1，抗生素，抗生素药物具有脂溶性高，与蛋白结合率低，分子量小以及离解度高等特点，阿奇霉素等抗生素药物具有高水平的组织穿透力，并且对细菌和支原体均有较高的活性，是临床上治疗慢性前列腺炎主要方式；2，α受体阻滞剂，使用受体阻滞剂让患者紧张的膀胱颈和前列腺组织变得松弛，从而消除排尿时前列腺内尿液返流，减少慢性前列腺炎的发生几率；3，高频透热治疗，前列腺组织在高频热的作用下，会发生血管扩张、代谢废物以及渗出物等现象，这会在一定程度 上加快患者体内物质的排出。非药物治疗包括盆底物理治疗、肌筋膜触发点释放、针灸、心理支持、电身体冲击波治疗、局部热疗等。
良性前列腺增生症(Benign Prostate Hyperplasia,BPH)是老年男性常见病,主要表现为尿频,尿急,排尿困难呈进行性加重,排尿无力,尿程缩短,尿不尽或淋漓。随着我国人口的老龄化,近年来其发病率呈上升趋势。前列腺增生的目前分为组织学前列腺增生和临床前列腺增生，组织学前列腺增生是一个生理老化过程。临床前列腺增生为病理型，表现为：前列腺体积增大，膀胱出口梗阻特征。前列腺增生发生的两个重要因素是：高龄和具有功能的睾丸，睾丸分泌的雄激素，转化为双氢睾酮后发挥作用，男性外生殖器的发育、青春期前列腺的生长、老年的前列腺增生等均需双氢睾酮的存在。雄激素还能刺激产生生长因子，前列腺可产生多种生长因子，包括表皮生长因子(EGF)，成纤维细胞生长因子(FGF)，β-转换生长因子(TGF-β)等，生长因子与生长抑制因子的相对平衡，前列腺才能正常发育，生长。BPH的治疗,主要有三种方式：1，药物治疗：5α-还原酶抑制剂能抑制双氢睾酮的产生，可以抑制前列腺组织持续增殖；前列腺受体α1拮抗剂(α受体阻滞剂)，对排尿困难的症状有缓解作用，但是药物治疗仅对轻度前列腺增生患者有一定的疗效，中重度患者的药物治疗疗效明显降低。中、重度前列腺增生患者需要手术治疗才能解除梗阻；2，开放手术包括：耻骨上经膀胱前列腺切除术、耻骨后前列腺切除术、耻骨后保留尿道前列腺切除术，开放手术存在创伤大、并发症多、术后恢复慢等缺陷；微创手术包括：经尿道前列腺切除，激光治疗，微 波治疗等，创伤小恢复快，但是可能会有病情的反复，老年前列腺增生患者由于年龄过大，一般同时患有多种疾病，可能不具备手术条件。
总体来说，慢性前列腺和前列腺增生目前临床尚未有突破性的进展，还缺乏针对老年男性较好的临床治疗方式。
前列腺是男性性器官，分泌前列腺液占精液成分的30％，前列腺管由假复层上皮细胞排列而成，主要有三种细胞类型：1)分泌腔细胞，以细胞角蛋白CK8/CK18、雄激素受体(AR)和前列腺特异性抗原(PSA)为标志；2)基底细胞，以CK5/CK14/p63为标志；3)罕见的神经内分泌细胞。
基底细胞表现为双重性，即能够产生管腔和基底细胞系，表明基底细胞具有潜能，也有研究表明，在人成熟前列腺中，基底细胞和腔细胞都含有干细胞活性。多能基底干细胞可以促进前列腺基底细胞、管腔细胞和神经内分泌细胞谱系的分化。
人前列腺前体样细胞的分离、持续培养的技术困难，目前的研究尚未完全攻克。目前对于前列腺上皮干样细胞的研究，主要以模型大鼠和小鼠的前列腺为主，将鼠前列腺组织消化分离后，经过流式分选获得CD44和CD133阳性的细胞为前列腺干样细胞，并在体外进行培养。
前列腺上皮由基底细胞、分泌管腔细胞和罕见的神经内分泌细胞组成，由于前列腺上皮在小鼠和大鼠体内经过反复的雄激素剥夺和恢 复后具有退化和再生的能力，可以作为研究前列腺干细胞生物学的细胞来源。研究人员通过体内肾包膜下组织再生、细胞分裂模型和体外类器官形成等分析方式，证明了前列腺基底和管腔上皮中都存在前列腺干样细胞。
多能基底干细胞可以促进前列腺基底细胞、管腔细胞和神经内分泌细胞谱系的分化，特别是在出生后早期发育期间。多能基底干细胞仅位于尿道旁壁龛，并以定向迁移的方式产生上皮祖细胞。而成年小鼠前列腺再生过程中，基底和腔细胞谱系是独立维持的。干细胞相关标志物(CD117、CD133、CD44、Trop2、CD49f、Sca1等)均存在于基底细胞和腔细胞。
前列腺炎症药物治疗需要的时间长，起效慢，都只能暂时缓解患者症状，多种治疗方式联合可取得疗效稍强于单一疗法，但是不良反应发生率和所需费用也相应增加，但是无论哪种治疗方式，都不能根治前列腺炎症，现代医学目前仍然无法明确慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)具体的发病机制，且对于CP/CPPS的管理和治疗未达到预期的疗效。
治疗前列腺增生的药物中，a受体阻剂起效快，对于不同位置的不同程度的前列腺肥大都有效，但只对症状比较轻、前列腺体积比较小的患者有良好的疗效，而且可能引起体位性低血压，5a还原酶抑制剂可以缩小前列腺体积，逆转疾病的进展，改善症状，但起效相对慢，一般需要连续服药2-3个月以上才起效，此外可能有勃起功能障 碍、性欲低下等症，植物药治疗前列腺
增生症的机制目前还不明确，目前仍然缺乏高质量、大规模、安慰剂对照的长程临床试验来进一步检验植物药疗法的有效性和安全性。
针对现有技术存在的问题，本发明的实施例提供了一种前列腺前体样细胞的制备方法，包括以下步骤：
S0：提供前列腺原代细胞。
前列腺原代细胞制备过程如下：
提供成熟的前列腺组织；使用无菌PBS缓冲液对成熟的前列腺组织进行清洗和灭菌处理后，使用由Ⅰ型胶原酶、无菌PBS缓冲液和中性蛋白酶消化液组成的3毫升细胞消化液在37摄氏度下对组织消化90分钟，从而获取原代细胞悬液。接着，使用70微米的无菌筛网对所述原代细胞悬液在无菌PBS缓冲液的辅助下进行筛网分选，收集滤液并去除粘液和未消化的组织，以完成筛网分选。然后，将得到的滤液离心并去除上清后，向得到的沉淀物加入红细胞溶解平衡液进行重悬后再次离心并重复上述过程直至再次离心后在细胞沉淀中观察不到红细胞为止，以完成红细胞裂解去除。
值得注意的是，在前列腺原代细胞制备过程，Ⅰ型胶原酶占无菌PBS缓冲液的体积百分比为1％，中性蛋白酶占无菌PBS缓冲液的体积 百分比为5％。每次离心的速率为1000g，离心时间为3分钟。
其中，Ⅰ型胶原酶来源于默克。中性蛋白酶来源于源叶生物。
S1：对所述S0中的前列腺原代细胞使用重编程培养基进行退分化培养以获得表达阳性标志物CD90、CD73、CD44和SOX9中至少一种的前列腺前体样细胞，其中，所述重编程培养基包括基础培养基、抑制剂和生长因子。
优选地，所述基础培养基为DMEM/F12培养基。
一种实施例中，所述的前列腺前体样细胞的制备方法，还包括：S2：将所述前列腺原代细胞放入重编程培养基中进行退分化培养，直至所述前列腺前体样细胞的融合度不低于80％，使用胰酶消化液对所述前列腺前体样细胞进行消化处理，以得到前列腺前体样细胞。可以通过该实施例的前列腺前体样细胞的制备方法，能够在体外持续传代培养。
一种实施例中，所述重编程培养基还包括Wnt信号通路激动剂、营养补充剂和缓冲液。
优选地，所述Wnt信号通路激动剂为CHIR99021，以占所述基础培养基的含量计，所述Wnt信号通路激动剂的含量为3μM。
优选地，所述营养补充剂包括N2(1X)和B27(1X)。所述N2(1X)的含量为培养基终体积的0.5％。所述B27(1X)的含量为培养基终体积 的1％。
一种实施例中，所述抑制剂包括抑制TGF-β信号通路的ROCK激酶抑制剂和A83-01抑制剂。
一种实施例中，所述ROCK激酶抑制剂为Y-27632。以占所述基础培养基的含量计，所述ROCK激酶抑制剂的含量为5-20μM，所述A83-01抑制剂的含量为1-5μM。其中，所述A83-01作为Alk3/4/5的抑制剂来抑制TGF-β信号通路，防止前列腺前体样细胞增殖受阻。
一种实施例中，所述生长因子包括EGF、bFGF、Noggin和R-spondin1。以占所述基础培养基的含量计，所述EGF的含量为10-50ng/mL，所述bFGF的含量为10-50ng/mL，所述Noggin的含量为1-10ng/mL，所述R-spondin1的含量为10-30ng/mL。其中，所述生长因子Noggin，为BMP-4拮抗剂，拮抗BMP活性可以使干细胞增殖，同时保持其未分化状态。所述生长因子R-spondin1可调节Wnt/β–catenin信号通路，可用于维持前列腺前体样细胞增殖。
一种实施例中，所述前列腺前体样细胞不表达CD34、CD45、HLA-DR、HLA-DP和HLA-DQ。所述CD34、CD45、HLA-DR、HLA-DP和HLA-DQ属于MHC二类分子，本发明中得到的前列腺前体样细胞不表达MHC二类分子，因此在移植前列腺前体样细胞后不需要服用抗排药，可以减少对人身体的伤害，本发明的前列腺前体样细胞在治疗前列腺炎的安全性更高，应用范围更广泛，患者接受度更强。
本发明还提供了一种前列腺前体样细胞，通过所述的前列腺前体样细胞的制备方法制备得到，并能特异性表达阳性标志物CD90、CD73、CD44和SOX9中的至少一种。
本发明还提供了一种所述的前列腺前体样细胞的应用，所述前列腺前体样细胞用于制备治疗前列腺炎或前列腺增生的前列腺前体样细胞制剂，使用所述前列腺前体样细胞制剂干预体内动物模型后考察对前列腺炎的影响。
一种实施例中，所述动物模型包括药物诱导的前列腺炎或前列腺增生模型。
本发明还提供了一种前列腺前体样细胞制剂，包括所述的表达阳性标志物CD90、CD73、CD44和SOX9中至少一种的前列腺前体样细胞，以及药学上可接受的载体。
本发明还提供了一种前列腺前体样细胞制剂的应用，使用所述的前列腺前体样细胞制剂干预体内动物模型。
以下通过具体的实施例进行详细说明：
实施例
一、起始组织性质以及来源合法性声明：
以临床良性前列腺增生手术后切除的组织或者供体捐献的正常 前列腺组织为来源，获取阳性表达CD90、CD73、CD44和SOX9的人前列腺前体样细胞。
具体的，所述前列腺组织经病理检查显示为正常前列腺组织。
具体的，所述临床良性前列腺增生手术后切除的组织或者供体捐献的正常前列腺组织为来源于年龄不超过70岁的患者的手术样本，患者经医学检查无传染性病毒感染，患者在术前6个月内未使用过类固醇激素药物。患者在术前对手术样本的获取目的充分知情，并签署了知情同意书。
二、前列腺原代细胞获取
提供成熟的前列腺组织；
使用无菌PBS缓冲液对所述成熟的前列腺组织进行清洗和灭菌处理后，使用由Ⅰ型胶原酶、无菌PBS缓冲液和中性蛋白酶消化液组成的3毫升细胞消化液在37摄氏度下对组织消化90分钟，从而获取原代细胞悬液。接着，使用70微米的无菌筛网对所述原代细胞悬液在无菌PBS缓冲液的辅助下进行筛网分选，收集滤液并去除粘液和未消化的组织，以完成筛网分选。然后，将得到的滤液离心并去除上清后，向得到的沉淀物加入红细胞溶解平衡液进行重悬后再次离心并重复上述过程直至再次离心后在细胞沉淀中观察不到红细胞为止，以完成红细胞裂解去除，得到前列腺原代细胞。所述前列腺原代细胞包括基底细胞、腔细胞和干细胞。
值得注意的是，在前列腺原代细胞制备过程，Ⅰ型胶原酶占无菌PBS缓冲液的体积百分比为1％，中性蛋白酶占无菌PBS缓冲液的体积百分比为5％。每次离心的速率为1000g，离心时间为3分钟。
三、前列腺前体样细胞体外培养
重编程培养基组分包括：以占重编程培养基的体积计，基础培养基DMEM/F12(来源于武汉普诺赛生命科技有限公司)，含量为20ng/mL的上皮细胞生长因子EGF，含量为50ng/mL的碱性成纤维细胞生长因子bFGF，含量为培养基终体积的0.5％营养补充剂N2(1X)，含量为培养基终体积的1％B27营养补充剂(1X)，含量为5-20μM的ROCK激酶抑制剂Y-27632，含量为3μM的Wnt信号通路激动剂CHIR99021，含量为1-5μM的TGF-β信号抑制剂A8301，含量为1-10ng/mL的促进胆管前体样细胞的增殖的Noggin和含量为10-30ng/mL的R-spondin1。
将前列腺前体样细胞以10000个/平方厘米的接种面积置于6孔板中，每孔加2毫升重编程培养基进行退分化培养，直至前列腺前体样细胞的融合度不低于80％后，使用胰酶消化液对前列腺前体样细胞进行1-5分钟的消化后，再继续使用重编程培养基进行扩增培养，扩增培养又可称为传代培养，前列腺前体样细胞可持续传代。
本发明还提供了前列腺前体样细胞在光学显微镜下的形态示意图，具体地，可参见图1，其中，图1为本发明提供的前列腺前体样细胞的光学显微下的形态示意图；从图1中可以看出，前列腺前体样 细胞，呈现多边形，聚集生长，可见通过该实施例中的重编程培养基能够体外扩增前列腺前体样细胞。
四、前列腺前体样细胞分别通过重编程培养基和基础培养基培养，并对标志物结果分析
1.重编程培养基和基础培养基分别对前列腺前体样细胞进行体外培养
重编程培养基培养组：
将前列腺前体样细胞以10000个/平方厘米的接种面积置于6孔板中，每孔加2毫升重编程培养基进行退分化培养，直至前列腺前体样细胞的融合度不低于80％后，使用胰酶消化液对前列腺前体样细胞进行1-5分钟的消化后，再继续使用重编程培养基进行扩增培养。
基础培养基培养组：将前列腺前体样细胞以10000个/平方厘米的接种面积置于6孔板中，每孔加2毫升基础培养基进行退分化培养，使用胰酶消化液对前列腺前体样细胞进行1-5分钟的消化后，再继续使用基础培养基进行扩增培养。
2.重编程培养基和基础培养基培养的前列腺前体样细胞中标志物含量表达情况
图2为本发明中前列腺前体样细胞分别经过重编程培养基和基础培养基扩增培养后其中的基底细胞标志物含量对照图；图3为本发明中前列腺前体样细胞分别经过重编程培养基和基础培养基扩增培养后其中的腔细胞标志物含量对照图；图4为本发明中前列腺前体样 细胞分别经过重编程培养基和基础培养基扩增培养后其中的干细胞标志物含量对照图；图5为本发明中前列腺前体样细胞分别经过重编程培养基和基础培养基扩增培养后其中的前列腺特异性标志物含量对照图。
其中，图2、图3、图4和图5中每个标志物均对应两根矩形柱，矩形柱表示标志物的相对含量，并且左侧矩形柱对应的是在基础培养基扩增培养的结果，右侧对应的是在重编程培养基扩增培养的结果。
图2中的基底细胞标志物包括CK14、CK5和P63，从图2中可以看出，上述标志物在重编程培养基扩增培养的结果均高于在基础培养基扩增培养的结果，可见，前列腺前体样细胞在重编程培养基中较之在基础培养基中能够扩增培养更多的基底细胞。
图3中的腔细胞标志物包括CK18、CK8和AR，从图3中可以看出，上述标志物在重编程培养基扩增培养的结果均高于在基础培养基扩增培养的结果，可见，前列腺前体样细胞在重编程培养基中较之在基础培养基中能够扩增培养更多的基底细胞。
图4中的干细胞标志物包括CD44、CD49b、CD133、CD117、Trop2、CD491、Sca-1和p63在重编程培养基扩增培养的结果均高于在基础培养基扩增培养的结果，可见，前列腺前体样细胞在重编程培养基中较之在基础培养基中能够扩增培养更多的具有干性特征细胞。
图5中的前列腺特异性标志物包括pbsn和MLX3-1，从图5中可以看出，上述标志物在重编程培养基扩增培养的结果均低于在基础培 养基扩增培养的结果，可见，重编程培养基可以维持前列腺前体细胞区去分化状态，不表达成熟前列腺组织细胞标记物。
五、对前列腺前体样细胞进行流式检测
图6为本发明实施例的前列腺前体样细胞的基因表达标志物CD44的情况示意图；图7为本发明实施例的前列腺前体样细胞的基因表达标志物CD73的情况示意图；图8为本发明实施例的前列腺前体样细胞的基因表达标志物HLA-DRPQ的情况示意图；图9为本发明实施例的前列腺前体样细胞的基因表达标志物SOX9的情况示意图；图10为本发明实施例的前列腺前体样细胞的基因表达标志物CD90的情况示意图。
使用重编程培养基对前列腺前体样细胞进行传代培养后，吸弃重编程培养基后用无菌PBS缓冲液润洗，然后用胰酶消化液对前列腺前体样细胞进行消化处理后再进行离心处理，其中，离心处理的转速为200g，离心处理的时间为5分钟，离心处理结束后收集细胞沉淀物；向细胞沉淀物中加入100微升染色缓冲液重悬细胞至流式管中，再分别加入5微升待测流式抗体孵育20分钟后每管用400微升染色缓冲液重悬后进行表面抗体流式检测，流式检测结果见图6、图7、图8、图9和图10。
参照图8，标志物HLA-DRPQ的阴性峰的阳性率为％，阴性峰的阴性率大于98％说明前列腺前体样细胞阴性表达该标志物，因此，本发明的胃粘膜上皮前体样细胞阴性表达HLA-DR、HLA-DP和HLA-DQ。图 6、图7、图9和图10，标志物CD44的阳性峰的阳性率为99.7％，标志物CD73的阳性峰的阳性率为99.8％，标志物SOX9的阳性峰的阳性率为87.9％，标志物CD90的阳性峰的阳性率为74.6％，阳性峰的阳性率介于70-99％说明前列腺前体样细胞阳性表达该标志物，因此，本发明的前列腺前体样细胞阳性表达CD44、CD73、SOX9和CD90。
六、前列腺前体样细胞制剂的制备
使用重编程培养基对前列腺前体样细胞进行传代培养后，吸弃重编程培养基后用无菌PBS缓冲液润洗，然后用胰酶消化液对前列腺前体样细胞进行消化处理后再进行离心处理，其中，离心处理的转速为200g，离心处理的时间为5分钟，离心处理结束后收集细胞沉淀物。将细胞沉淀物用生理盐水注射液(石家庄四药)重悬后，计数细胞密度，并用生理盐水注射液定容至需要的细胞密度。
七、前列腺前体样细胞制剂在动物适应症模型中的应用，并进行效果论证：
大鼠急性前列腺炎模型
1.本实施例提供了大鼠急性前列腺炎模型的建模方法，并使用前列腺前体样细胞对大鼠前列腺炎模型进行干预，考察前列腺前体样细胞对前列腺炎的作用。
本实施例使用购自北京维通利华的雄性性成熟的10-12周龄野生型SD大鼠进行建模。大鼠的体重平均达到300g。每组3只大鼠。
大鼠前列腺炎模型的建立：大鼠腹腔注射10％水合氯醛，一至两 分钟后，将其平卧于超净台上，与阴茎根部上方2～3cm正中线两侧皮下各注射0.1ml盐酸利多卡因，做1～2cm纵行切口，逐层切开皮肤筋膜，到达肌肉组织是上皮肌肉向下切一小口，出现踏空感后，使用止血钳进入腹腔钝性分离机组织提起膀胱其后方找到颜色较深的前列腺两侧叶向两侧分别注射3％卡拉胶，30～50微升，注射完成后将膀胱和前列腺回纳腹腔逐层缝合切口建模一周后，各组大鼠进行测控实验，模型建立过程可参见图13，图13为本发明中大鼠前列腺炎模型建立过程示意图。
将大鼠前列腺炎模型随机分为假手术组(3只)、空白对照组(3只)和细胞治疗组(3只)。
假手术组，大鼠腹腔注射10％水合氯醛，一至两分钟后，将其平卧于超净台上，与阴茎根部上方2～3cm正中线两侧皮下各注射0.1ml盐酸利多卡因，做1～2cm纵行切口，逐层切开皮肤筋膜，到达肌肉组织是上皮肌肉向下切一小口，出现踏空感后，使用止血钳进入腹腔钝性分离机组织提起膀胱其后方找到颜色较深的前列腺两侧叶向两侧分别注射3％卡拉胶，30～50微升，注射完成后将膀胱和前列腺回纳腹腔逐层缝合切口，不进行细胞注射治疗，仅进行前列腺炎造模。
空白对照组，不进行操作，与实验组和假手术组动物同时入组，一直饲养。
前列腺前体样细胞治疗组：在建模同时对细胞治疗组大鼠的两侧叶各注射50ul的前列腺前体样细胞注射1E+06 50ul+50ul matrigel 基质胶；建模后一周，对细胞治疗组大鼠的两侧叶再次各注射50ul的前列腺前体样细胞注射1E+06 50ul+50ul matrigel基质胶。
2.动物实验血液炎症指标
收集各组大鼠外周血100ul，分离血清，Elisa检测法IL-1a、IL-6表达水平。实验前基础值和实验后不同时间点及终点(术前、7d、21d)。其中，所述IL-1a、IL-6属于炎性分子。
图14为假手术组、空白对照组和前列腺前体样细胞治疗组采用Elisa检测法检测IL-6表达水平示意图；图15为假手术组、空白对照组和前列腺前体样细胞治疗组采用Elisa检测法检测IL-1a表达水平示意图。
从图14和图15中可以看出，前体样细胞治疗组相对炎性细胞浸润较空白对照组显著下降。炎性细胞理解为发生炎症反应相关的细胞。
3.前列腺炎病理分析(HE染色)
手术21天对假手术组、空白对照组和前列腺前体样细胞治疗组内的大鼠分别取样做前列腺病例切片，并进行HE染色，HE染色具体如下：
(1)石蜡切片脱蜡至水
依次将切片放入二甲苯Ⅰ10min-二甲苯Ⅱ10min-无水乙醇Ⅰ5min-无水乙醇Ⅱ5min-95％酒精5min-90％酒精5min-80％酒精5min-70％酒精5min-蒸馏水洗。
(2)苏木素染细胞核
切片入Harris苏木素染3-8min，自来水洗，1％的盐酸酒精分化数秒，自来水冲洗，0.6％氨水返蓝，流水冲洗。
(3)伊红染细胞质
切片入伊红染液中染色1-3min。
(4)脱水封片
将切片依次放入95％酒精I 5min-95％酒精II 5min-无水乙醇Ⅰ 5min-无水乙醇Ⅱ 5min-二甲苯Ⅰ 5min-二甲苯Ⅱ 5min中脱水透明，将切片从二甲苯拿出来稍晾干，中性树胶封片。
(5)显微镜镜检，图像采集分析
图16为本发明中假手术组、空白对照组和前列腺前体样细胞治疗组中分别对前列腺病例切片HE染色的荧光照片。
从图16中可知，假手术组前列腺组织腺体完整，无炎症细胞浸润，空白对照组可见不等量的组织变性，前列腺腺体水肿或增生，间质内炎性细胞大量浸润。
综上，假手术组前列腺组织腺体完整，无炎症细胞浸润，空白对照组可见不等量的组织变性，前列腺腺体水肿或增生，间质内炎性细胞大量浸润，前体样细胞治疗组相对炎性细胞浸润较空白对照组显著下降。
八、大鼠前列腺增生模型
建模过程：丙酸睾酮，50mg每公斤，隔天一次皮下注射，注射3周。
假手术组：本实施例使用购自北京维通利华的雄性10-12周龄野生型SD大鼠进行建模。大鼠的体重平均达到300g，每组3只大鼠，按照50mg每公斤剂量，皮下注射丙酸睾酮，共注射2次，间隔1天。不进行细胞给药治疗。
空白对照组：不进行操作，与实验组和假手术组动物同时入组，一直饲养。
前列腺前体样细胞治疗组：大鼠腹腔注射10％水合氯醛，一至两分钟后，将其平卧于超净台上，与阴茎根部上方2～3cm正中线两侧皮下各注射0.1ml盐酸利多卡因，做1～2cm纵行切口，逐层切开皮肤筋膜，到达肌肉组织是上皮肌肉向下切一小口，出现踏空感后，使用止血钳进入腹腔钝性分离机组织提起膀胱其后方找到颜色较深的前列腺两侧叶，前列腺前体样细胞1E+06/50ul与50ul matrigel基质胶混匀后，注射到前列腺两侧叶；并且按照50mg每公斤剂量，皮下注射丙酸睾酮。
间隔一天，再次按照50mg每公斤剂量，皮下注射丙酸睾酮。
建模后一周，对细胞治疗组大鼠的两侧叶再次各注射1E+06/50ul的前列腺前体样细胞l+50ul matrigel基质胶。
术后21天取样病理切片，并进行HE染色；
图17为本发明中前列腺增生模型病理结果；如图17所示，假手 术组前列腺组织腺体完整，无炎症细胞浸润，空白对照组可见组织变性，前列腺腺体增生，前体样细胞治疗组组织变性和腺体增生较空白对照组显著下降。
可见，假手术组前列腺组织腺体完整，无炎症细胞浸润，空白对照组可见组织变性，前列腺腺体增生，前体样细胞治疗组组织变性和腺体增生较空白对照组显著下降。
综上，根据对前列腺前体样细胞培养后的表面标志物检测，发现该前列腺前体样细胞标志物为阳性表达CD90、CD73、CD44和SOX9的细胞，并且在体外培养时外观呈现典型的前体样细胞特征。可以用于后续的前列腺炎症和增生的机制研究，可以进行体外细胞层面的各种实验。
而且培养获得的前列腺前体样细胞，在进行动物实验时，前列腺炎模型中，细胞回输治疗后，可以显著降低血液炎性因子IL-6以及IL-2a的水平，和前列腺组织炎症的程度。并且，在前列腺增生模型中，细胞回输后可以使前列腺增生改善。
并且，由于前列腺前体样细胞表面不表达于免疫排斥反应相关的蛋白CD34、CD45、HLA-DR、HLA-DP和HLA-DQ，因此可以实现前列腺前体样细胞的异体回输，以临床良性前列腺增生手术后切除的组织或者供体捐献的正常前列腺组织为来源，取前列腺组织消化后得到的原代前列腺细胞作为种子细胞，使用重编程培养基进行体外培养，获得阳性表达CD90、CD73、CD44和SOX9的前列腺前体样细胞，并且进行 体外扩增建立细胞种子库。在用于治疗临床前列腺炎、前列腺增生时，可直接原位注射前列腺前体样细胞。
虽然在上文中详细说明了本发明的实施方式，但是对于本领域的技术人员来说显而易见的是，能够对这些实施方式进行各种修改和变化。但是，应理解，这种修改和变化都属于权利要求书中所述的本发明的范围和精神之内。而且，在此说明的本发明可有其它的实施方式，并且可通过多种方式实施或实现。

Claims (13)

  1. 一种前列腺前体样细胞的制备方法，其特征在于，包括以下步骤：
    S0：提供前列腺原代细胞；
    S1：对所述S0中的前列腺原代细胞使用重编程培养基进行退分化培养以获得表达阳性标志物CD90、CD73、CD44和SOX9中至少一种的前列腺前体样细胞，其中，所述重编程培养基包括基础培养基、抑制剂和生长因子。
  2. 根据权利要求1所述的前列腺前体样细胞的制备方法，其特征在于，还包括：
    S2：将所述前列腺原代细胞放入重编程培养基中进行退分化培养，直至所述前列腺前体样细胞的融合度不低于80％，使用胰酶消化液对所述前列腺前体样细胞进行消化处理，以得到前列腺前体样细胞。
  3. 根据权利要求2所述的前列腺前体样细胞的制备方法，其特征在于，所述重编程培养基还包括Wnt信号通路激动剂、营养补充剂和缓冲液。
  4. 根据权利要求1所述的前列腺前体样细胞的制备方法，其特征在于，所述抑制剂包括抑制TGF-β信号通路的ROCK激酶抑制剂和A83-01抑制剂。
  5. 根据权利要求4所述的前列腺前体样细胞的制备方法，其特征在于，以占所述基础培养基的含量计，所述ROCK激酶抑制剂的含量为5-20μM，所述A83-01抑制剂的含量为1-5μM。
  6. 根据权利要求1所述的前列腺前体样细胞的制备方法，其特征在于，所述生长因子包括EGF、bFGF、Noggin和R-spondin1。
  7. 根据权利要求6所述的前列腺前体样细胞的制备方法，其特征在于，以占所述基础培养基的含量计，所述EGF的含量为10-50ng/mL，所述bFGF的含量为10-50ng/mL，所述Noggin的含量为1-10ng/mL，所述R-spondin1的含量为10-30ng/mL。
  8. 根据权利要求1所述前列腺前体样细胞的制备方法，其特征在于，所述前列腺前体样细胞不表达CD34、CD45、HLA-DR、HLA-DP和HLA-DQ。
  9. 一种前列腺前体样细胞，其特征在于，通过权利要求1至8中任一项所述的前列腺前体样细胞的制备方法制备得到，并能特异性表达阳性标志物CD90、CD73、CD44和SOX9中的至少一种。
  10. 一种如权利要求9所述的前列腺前体样细胞的应用，其特征在于，所述前列腺前体样细胞用于制备治疗前列腺炎或前列腺增生的前列腺前体样细胞制剂，使用所述前列腺前体样细胞制剂干预体内动物模型后考察对前列腺炎的影响。
  11. 根据权利要求10所述的前列腺前体样细胞的应用，其特征在于，所述动物模型包括药物诱导的前列腺炎或前列腺增生模型。
  12. 一种前列腺前体样细胞制剂，其特征在于，包括如权利要求9所述的表达阳性标志物CD90、CD73、CD44和SOX9中至少一种的前列腺前体样细胞，以及药学上可接受的载体。
  13. 一种前列腺前体样细胞制剂的应用，其特征在于，使用如权利要求12中所述的前列腺前体样细胞制剂干预体内动物模型。
PCT/CN2023/092958 2022-05-10 2023-05-09 前列腺前体样细胞、细胞制剂及其制备方法和应用 WO2023217125A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210503678 2022-05-10
CN202210503678.6 2022-05-10

Publications (1)

Publication Number Publication Date
WO2023217125A1 true WO2023217125A1 (zh) 2023-11-16

Family

ID=88621424

Family Applications (9)

Application Number Title Priority Date Filing Date
PCT/CN2023/092965 WO2023217130A1 (zh) 2022-05-10 2023-05-09 包含骨骼肌前体样细胞的生物制剂及其制备方法和应用
PCT/CN2023/092963 WO2023217128A1 (zh) 2022-05-10 2023-05-09 胃粘膜上皮前体样细胞及其制备方法和应用
PCT/CN2023/092959 WO2023217126A1 (zh) 2022-05-10 2023-05-09 肾上皮前体样细胞及其制备方法、制剂和应用
PCT/CN2023/092954 WO2023217121A1 (zh) 2022-05-10 2023-05-09 含肾前体样细胞的生物制剂及其制备方法和应用
PCT/CN2023/092958 WO2023217125A1 (zh) 2022-05-10 2023-05-09 前列腺前体样细胞、细胞制剂及其制备方法和应用
PCT/CN2023/092956 WO2023217123A1 (zh) 2022-05-10 2023-05-09 肺前体样细胞的制备方法和应用
PCT/CN2023/092967 WO2023217132A1 (zh) 2022-05-10 2023-05-09 胆囊前体样细胞的制备方法和应用
PCT/CN2023/092964 WO2023217129A1 (zh) 2022-05-10 2023-05-09 肝内胆管前体样细胞、细胞制剂及制备方法和应用
PCT/CN2023/092969 WO2023217134A1 (zh) 2022-05-10 2023-05-09 包含心肌前体样细胞的生物制剂及其制备方法和应用

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PCT/CN2023/092965 WO2023217130A1 (zh) 2022-05-10 2023-05-09 包含骨骼肌前体样细胞的生物制剂及其制备方法和应用
PCT/CN2023/092963 WO2023217128A1 (zh) 2022-05-10 2023-05-09 胃粘膜上皮前体样细胞及其制备方法和应用
PCT/CN2023/092959 WO2023217126A1 (zh) 2022-05-10 2023-05-09 肾上皮前体样细胞及其制备方法、制剂和应用
PCT/CN2023/092954 WO2023217121A1 (zh) 2022-05-10 2023-05-09 含肾前体样细胞的生物制剂及其制备方法和应用

Family Applications After (4)

Application Number Title Priority Date Filing Date
PCT/CN2023/092956 WO2023217123A1 (zh) 2022-05-10 2023-05-09 肺前体样细胞的制备方法和应用
PCT/CN2023/092967 WO2023217132A1 (zh) 2022-05-10 2023-05-09 胆囊前体样细胞的制备方法和应用
PCT/CN2023/092964 WO2023217129A1 (zh) 2022-05-10 2023-05-09 肝内胆管前体样细胞、细胞制剂及制备方法和应用
PCT/CN2023/092969 WO2023217134A1 (zh) 2022-05-10 2023-05-09 包含心肌前体样细胞的生物制剂及其制备方法和应用

Country Status (2)

Country Link
CN (9) CN117025503A (zh)
WO (9) WO2023217130A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115948331A (zh) * 2022-10-17 2023-04-11 中国人民解放军西部战区总医院 一种从小鼠胆囊中分离获取间充质干细胞的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130309681A1 (en) * 2010-11-12 2013-11-21 Georgetown University Immortalization of Epithelial Cells and Methods of Use
CN104152398A (zh) * 2013-05-13 2014-11-19 百奥迈科生物技术有限公司 前列腺组织分离和建立原代上皮细胞和/或间质细胞的方法
CN107636149A (zh) * 2015-04-03 2018-01-26 普罗帕格尼克斯公司 上皮细胞的离体增殖
CN109477070A (zh) * 2016-03-01 2019-03-15 荷兰皇家科学院 改进的分化方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10590391B2 (en) * 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US8642339B2 (en) * 2009-02-03 2014-02-04 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
CA2781522A1 (en) * 2009-10-19 2011-04-28 Tristem Trading (Cyprus) Limited Treatment using reprogrammed mature adult cells
BR112014007676A2 (pt) * 2011-09-30 2017-04-18 The Univ Of Miami células-tronco renais isoladas do rim
CN103031270A (zh) * 2013-01-05 2013-04-10 绍兴文理学院 胆管上皮细胞的高效扩增和培养方法
ITFI20130303A1 (it) * 2013-12-24 2015-06-25 Azienda Ospedaliero Universitaria M Eyer Metodica per l¿isolamento, purificazione ed amplificazione di progenitori renali cd133+cd24+ dalle urine di pazienti affetti da malattie renali.
CN103860597A (zh) * 2014-03-03 2014-06-18 奥思达干细胞有限公司 一种治疗缺血性心肌病的干细胞制剂及其制备方法
US9687512B2 (en) * 2014-03-12 2017-06-27 Banner Health Isolated cardiac stem cells and methods of their use
KR101987395B1 (ko) * 2014-05-01 2019-06-10 아이하트 재팬 가부시키가이샤 Cd82 양성 심근 전구세포
US10258652B2 (en) * 2014-12-18 2019-04-16 Pluristem Ltd. Methods and compositions for treating and preventing muscle wasting disorders
KR101782488B1 (ko) * 2015-05-19 2017-09-28 주식회사 스템랩 Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법
CN104928235A (zh) * 2015-07-10 2015-09-23 奥思达干细胞有限公司 基于干细胞的组合物及其在制备用于冠心病的制剂中的应用
CA2998372A1 (en) * 2015-09-11 2017-03-16 Chengkang ZHANG Ex vivo proliferation of epithelial cells
CN106754636B (zh) * 2015-11-19 2019-08-30 中国人民解放军第二军医大学 体外诱导原代肝细胞胆管化并长期培养、扩增和分化的方法及其应用
JP2017108705A (ja) * 2015-12-18 2017-06-22 国立大学法人京都大学 心筋細胞の製造方法
EP3450546B1 (en) * 2016-04-27 2024-03-13 Takeda Pharmaceutical Company Limited Skeletal muscle precursor cells and production method for skeletal muscle cells
JP7089484B2 (ja) * 2016-06-01 2022-06-22 ミルテニイ ビオテック ベー．ファー． ウント コー．カーゲー ヒト多能性幹細胞由来の心筋細胞および心筋細胞サブポピュレーションの生成、同定ならびに単離のための方法
CN107099499B (zh) * 2016-06-03 2021-02-02 中国人民解放军军事医学科学院野战输血研究所 将消化道来源上皮细胞重编程为内胚层干/祖细胞的小分子化合物组合、重编程试剂盒
CN107151645A (zh) * 2017-05-16 2017-09-12 武汉大学深圳研究院 一种为肺癌提供离体个体化药物测试的方法及培养基
GB201709704D0 (en) * 2017-06-19 2017-08-02 Cambridge Entpr Ltd Methods of expanding cholangiocytes
CN108570443A (zh) * 2017-12-05 2018-09-25 皓昇莱生物制药有限公司 一种用于培养尿液来源细胞的培养基
CN110218696A (zh) * 2018-03-01 2019-09-10 中国科学院广州生物医药与健康研究院 一种用于化学诱导多能性干细胞生成的培养体系以及使用该培养体系的化学重编程方法
WO2019210279A1 (en) * 2018-04-27 2019-10-31 The Regents Of The University Of California De novo formation of the biliary system by hepatocyte transdifferentiation
BR112020022667A2 (pt) * 2018-05-08 2021-02-09 Universität Zürich método para gerar uma população de células precursoras do músculo humano derivadas do músculo esquelético, população de células precursoras do músculo humano derivado do músculo esquelético, meio de crescimento celular para produção de uma população de células precursoras do músculo humano, método para a produção de um meio de crescimento celular, método para a produção de uma composição e composição
KR102071302B1 (ko) * 2018-06-28 2020-01-30 한국과학기술연구원 엑소좀 기반의 심근세포 교차분화 유도방법
CN109576215A (zh) * 2018-12-27 2019-04-05 广州赛莱拉干细胞科技股份有限公司 一种诱导牙髓干细胞向心肌样细胞分化的方法
AU2020256247A1 (en) * 2019-04-03 2021-10-28 The Johns Hopkins University Methods, compositions, and kits for producing skeletal muscle stem cells and treating disorders
KR102150489B1 (ko) * 2019-04-09 2020-09-01 고려대학교 산학협력단 소변세포로부터 신장전구세포로의 직접 역분화를 유도하는 방법 및 이의 방법으로 역분화된 신장전구세포를 포함하는 신장세포 손상 질환 예방 또는 치료용 약학 조성물
CN110184299B (zh) * 2019-04-23 2023-11-24 中国科学院广州生物医药与健康研究院 诱导体细胞重编程的因子以及使用该因子诱导体细胞重编程的方法
CN112126618B (zh) * 2019-06-24 2023-09-12 上海拜羡生物科技有限公司 一种人胆囊干细胞的获取和长期体外培养的方法
WO2021047495A1 (zh) * 2019-09-12 2021-03-18 海门雨霖细胞科技有限责任公司 体内外化学诱导成纤维细胞直接重编程为肝细胞的化学小分子组合物及方法
CN111440761A (zh) * 2020-04-09 2020-07-24 上海赛尔维医疗科技有限公司 胰腺细胞的扩增和分化方法以及应用
CN115322947B (zh) * 2022-06-25 2024-02-09 同济大学 一种采用成体肾前体细胞经悬浮分化培养构建肾微器官的方法和应用
CN115992090A (zh) * 2022-11-09 2023-04-21 同济大学 一种肾前体细胞来源的分泌组及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130309681A1 (en) * 2010-11-12 2013-11-21 Georgetown University Immortalization of Epithelial Cells and Methods of Use
CN104152398A (zh) * 2013-05-13 2014-11-19 百奥迈科生物技术有限公司 前列腺组织分离和建立原代上皮细胞和/或间质细胞的方法
CN107636149A (zh) * 2015-04-03 2018-01-26 普罗帕格尼克斯公司 上皮细胞的离体增殖
CN109477070A (zh) * 2016-03-01 2019-03-15 荷兰皇家科学院 改进的分化方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MCKEEHAN WALLACE L, ADAMS PAMELA S, ROSSER MARY P, : "Direct Mitogenic Effects of Insulin, Epidermal Growth Factor, Glucocorticoid, Cholera Toxin, Unknown Pituitary Factors and Possibly Prolactin, but not Androgen, on Normal Rat Prostate Epithelial Cells in Serum-free, Primary Cell Culture1", CANCER RESEARCH, vol. 44, no. 5, 1 May 1984 (1984-05-01), pages 1998 - 2010, XP093106830 *
YU-LING JIA, LI ZHOU, ZU-YUE SUN: "Progress of Study on Methods of Pharmacological Experiments of Prostatitis", LETTERS IN BIOTECHNOLOGY, JUNSHI YIXUE KEXUEYUAN, CN, vol. 24, no. 4, 30 July 2013 (2013-07-30), CN , pages 579 - 583, XP093106827, ISSN: 1009-0002, DOI: 10.3969/j.issn.1009-0002.2013.04.032 *

Also Published As

Publication number Publication date
CN117025505A (zh) 2023-11-10
CN117025502A (zh) 2023-11-10
CN117025508A (zh) 2023-11-10
WO2023217123A1 (zh) 2023-11-16
WO2023217132A1 (zh) 2023-11-16
WO2023217121A1 (zh) 2023-11-16
WO2023217129A1 (zh) 2023-11-16
WO2023217128A1 (zh) 2023-11-16
CN117025506A (zh) 2023-11-10
CN117025504A (zh) 2023-11-10
CN117025507A (zh) 2023-11-10
CN117025503A (zh) 2023-11-10
WO2023217126A1 (zh) 2023-11-16
CN117018032A (zh) 2023-11-10
WO2023217130A1 (zh) 2023-11-16
WO2023217134A1 (zh) 2023-11-16
CN117018033A (zh) 2023-11-10

Similar Documents

Publication Publication Date Title
Stangel‐Wojcikiewicz et al. Autologous muscle‐derived cells for the treatment of female stress urinary incontinence: a 2‐year follow‐up of a polish investigation
US9617516B2 (en) Muscle-derived cells (MDCs) for promoting and enhancing nerve repair and regeneration
Ryu et al. Intracavernous delivery of clonal mesenchymal stem cells restores erectile function in a mouse model of cavernous nerve injury
WO2023217125A1 (zh) 前列腺前体样细胞、细胞制剂及其制备方法和应用
US20110008299A1 (en) Treatment of pelvic floor disorders with an adipose-derived cell composition
Peak et al. Current perspectives on stem cell therapy for erectile dysfunction
CN112094813B (zh) 培养失分化或未分化甲状腺癌类器官的方法及甲状腺癌培养基
Chun et al. Combined injection of three different lineages of early‐differentiating human amniotic fluid‐derived cells restores urethral sphincter function in urinary incontinence
EP2486930B1 (en) Cell preparation containing adipose tissue derived mesenchymal stem cells for use in the treatment of a condition of no urge to urinate
Hu et al. Long-term transplantation human menstrual blood mesenchymal stem cell loaded collagen scaffolds repair endometrium histological injury
Gopinath et al. Human umbilical cord blood derived stem cells repair doxorubicin-induced pathological cardiac hypertrophy in mice
Li et al. Effects of local injection and intravenous injection of allogeneic bone marrow mesenchymal stem cells on the structure and function of damaged anal sphincter in rats
US20180280446A1 (en) Agent for Treating Urinary Incontinence Including Stem Cells Derived from Amniotic Fluid
WO2020228819A1 (zh) 一种临床级自体支气管基底层细胞及回输制剂和制备工艺
US20230193276A1 (en) Composition of drug targets and method of using thereof
EP1690929A1 (en) Regeneration treatment system
Singh et al. Current approaches for the regeneration and reconstruction of ocular surface in dry eye
Li et al. Stem-cell therapy in stress urinary incontinence: A review
WO2023216104A1 (zh) 子宫内膜修复相关制剂、子宫内膜细胞及制备方法和应用
WO2022218443A1 (zh) 间充质干细胞来源的外泌体治疗脑卒中的方法和组合物
WO2023274043A1 (zh) 一种人泪腺干细胞及其分化培养方法与应用
US20140050705A1 (en) Agent for treating urinary incontinence including stem cells derived from amniotic fluid
WO2014057097A1 (en) Modulated mesenchymal stem cells for cardiac cell therapy
Hendawy et al. Cultured versus freshly isolated adipose-derived stem cells in improvement of the histopathological outcomes in HCL-induced cystitis in a rat model
CN109749981B (zh) 人源脂肪干细胞来源的肝细胞样细胞及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23802894

Country of ref document: EP

Kind code of ref document: A1